All In Biotech

Drug Trial Radar · NCT06239480

SELVA: A Phase 3 Study Evaluating QTORIN 3.9% Rapamycin Anhydrous Gel in the Treatment of Microcystic Lymphatic Malformations

SELVA: A Multicenter, Phase 3 Baseline-Controlled Study Evaluating the Safety and Efficacy of QTORIN 3.9% Rapamycin Anhydrous Gel in the Treatment of Microcystic Lymphatic Malformations

Last checked: Nov 20, 2026Latest source record: Mar 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

51

Actual

Start

Jul 31, 2024

Primary completion

Jan 14, 2026

Study completion Jul 2026

Sponsor

Lead sponsor
Palvella Therapeutics, Inc.Industry
Sponsor type
Industry
Collaborators
FDA Office of Orphan Products Development
First posted
Feb 2, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 3 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

SELVA: A Multicenter, Phase 3 Baseline-Controlled Study Evaluating the Safety and Efficacy of QTORIN 3.9% Rapamycin Anhydrous Gel in the Treatment of Microcystic Lymphatic Malformations The main purpose of this study is to assess the change in microcystic lymphatic malformations IGA after 24 weeks of treatment with QTORIN 3.9% Rapamycin Anhydrous Gel in approximately 40 participants with microcystic lymphatic malformations. Efficacy will be evaluated at 24 weeks and patients have the option of continuing on treatment for \>24 weeks.

Conditions

  • Microcystic Lymphatic Malformation

Interventions

  • QTORIN 3.9% Rapamycin Anhydrous GelDrug

    QTORIN 3.9% Rapamycin Anhydrous Gel

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall microcystic lymphatic malformations Investigator Global Assessment (mLM-IGA)Time frame: At Week 24

Locations

15 sites in 1 country. Site status is shown where the registry gives one.

  • Children's Hospital of Orange County

    Irvine, California

  • Stanford University

    Palo Alto, California

  • Children's Healthcare of Atlanta

    Atlanta, Georgia

  • Minnesota Clinical Study Center

    New Brighton, Minnesota

  • Mayo Clinic

    Rochester, Minnesota

  • Vascular Birthmark Institute

    New York, New York

  • University of North Carolina

    Chapel Hill, North Carolina

  • Cincinnati Children's Hospital

    Cincinnati, Ohio

  • Cleveland Clinic

    Cleveland, Ohio

  • Penn State Hershey Medical Center

    Hershey, Pennsylvania

  • Children's Hospital of Philadelphia

    Philadelphia, Pennsylvania

  • Vanderbilt Children's Hospital

    Nashville, Tennessee

  • University of Texas, Dell Children's

    Austin, Texas

  • Texas Children's Hospital

    Houston, Texas

  • University of Utah Health

    Salt Lake City, Utah

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.